Patents Assigned to Universite de Montpellier
  • Methods for diagnosing hematological cancers
    Patent number: 10969391
    Abstract: The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: April 6, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Martin Villalba Gonzalez, Ewelina Krzywinska
  • USE OF QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20210087145
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Application
    Filed: December 7, 2020
    Publication date: March 25, 2021
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Romain NAJMAN, Florence MAHUTEAU, Didier SCHERRER, Karim CHEBLI, Michael HAHNE
  • Targeted and mutated human-interferon fusion proteins
    Patent number: 10946070
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCK
    Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
  • Phosphinolactone derivatives and pharmaceutical uses thereof
    Patent number: 10947260
    Abstract: A compound of following formula (I): where: X is O or S; A is an aromatic (hetero)cycle having 5 to 10 atoms selected from among carbon and nitrogen atoms, optionally being substituted; R? is H or (C1-C6)alkyl group; R1, R2, R3, R4 and R5, the same or different, are selected from the group formed by: H, (C1-C6)alkyl groups and (C6-C10)aryl groups. The compound is for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 16, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE PRATIQUE DES HAUTES ETUDES, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Tangui Maurice, Jean-Noël Volle, David Virieux, Jean-Luc Pirat, Coralie Laborde
  • Targeting of human interferon antagonists
    Patent number: 10947288
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • PHASE CHANGE OPTICAL DEVICE
    Publication number: 20210071083
    Abstract: An optical device including an aerogel located in an encapsulating structure, an optically non isotropic material presenting a refractive index which can be changed upon submitting said material to an electrical field, preferentially a liquid crystal mixture, embedded in the aerogel, and first and second electrodes arranged to generate an electric field in the encapsulating structure.
    Type: Application
    Filed: January 29, 2019
    Publication date: March 11, 2021
    Applicants: Essilor International, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS
    Inventors: Samuel ARCHAMBEAU, Claudine BIVER, Pascal ETIENNE, Sylvie CALAS ETIENNE, Laurent BONNET
  • Use of novel compounds for selectively extracting rare earths from aqueous solutions including phosphoric acid and associated extraction method
    Patent number: 10934604
    Abstract: The invention relates to the use, as an extraction agent for extracting at least one rare earth from an aqueous phase including phosphoric acid, of at least one compound of the following general formula (I): where n is an integer equal to 0, 1 or 2, R1 and R2 are H or an aliphatic hydrocarbon group, one of R3 and R4 has the following formula (II): where R5 and R6 are a hydrocarbon, hydroxyl or alkoxyl group, and the other one of R3 and R4 has one of the following formulas (II?) and (III): where R5? and R6? are a hydrocarbon, hydroxyl or alkoxyl group, and R7 and R8 are H or an aliphatic hydrocarbon group. The invention also relates to a method for recovering at least one rare earth using said compound, as well as to specific compounds as such.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: March 2, 2021
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Fanny Mary, Guilhem Arrachart, Stephane Pellet-Rostaing, Antoine Leydier, Veronique Dubois
  • USE OF QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20210047273
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Application
    Filed: August 17, 2020
    Publication date: February 18, 2021
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN
  • Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells
    Patent number: 10920198
    Abstract: The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of ?133?536 isoform, ?133?53? isoform, or both ?133?536 and ?133?53? isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in ?133?536 isoform, ?133?53? isoform, or both ?133?536 and ?133?53? isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing ?133p536 isoform, ?133?53? isoform, or both ?133?536 and ?133?53? isoforms expression; and also to screening methods for anti-cancer stem cells agents.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: February 16, 2021
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier
    Inventors: Pierre Roux, Nikola Arsic, Gilles Gadea, Philippe Fort, Fanny Thomas, Véronique Gire
  • Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor
    Patent number: 10894803
    Abstract: The subject matter of the present invention is a compound characterized in that it has the general formula (I): in which P1, X, n, A, L and L1 are as defined in Claim 1. The present invention also relates to a process for preparing said compounds (I) and to the use thereof for targeting the cation-independent mannose 6-phosphate receptor (CI-M6PR). The subject matter of the invention is also a conjugate of formula (III): in which P1, X, n, A, L and L?1 are as defined in Claim 6, and the use thereof: —in a method for therapeutic treatment of the human or animal body, in particular chosen from enzyme replacement therapy, photodynamic therapy or cancer treatment, and/or—in a method of diagnosis, in particular of diseases or of ailments associated with an increase or with a decrease in CI-M6PR expression.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: January 19, 2021
    Assignees: NANOMEDSYN, Centre National de la Recherche Scientifique, Universite de Montpellier
    Inventors: Alain Morere, Afitz Da Silva, Elise Bouffard, Khaled El Cheikh, Jean-Olivier Durand, Marie Maynadier, Ilaria Basile
  • Process for extracting and recovering tantalum present in an acid aqueous phase by means of an ionic liquid, and use of such an ionic liquid for extracting the tantalum from an acid aqueous phase
    Patent number: 10844459
    Abstract: A method for extracting the tantalum from an acid aqueous phase A1 comprising at least one step comprising the bringing of the aqueous phase A1 into contact with a phase A2 not miscible with water, and then the separation of the aqueous phase A1 from the phase A2, the phase A2 consisting of one ionic liquid or a mixture of ionic liquids as an extractant. A method for recovering the tantalum that implements this extraction method and to a use of an ionic liquid or of a mixture of ionic liquids as an extractant, in order to extract the tantalum from such an aqueous phase A1.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: November 24, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, UNIVERSITE DE CHAMBERY, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, TND, UNIVERSITE DE LORRAINE
    Inventors: Raphael Turgis, Guilhem Arrachart, Stéphane Pellet-Rostaing, Micheline Draye, Sophie Legeai, David Virieux, Christian Thomas
  • New Uses of Lipophenolic Compounds
    Publication number: 20200360334
    Abstract: The present invention relates to compound of formula (I): wherein R is O—R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, —CO—(C1-C21)alkyl or —CO—(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a —CO—(C11-C21)alkyl or —CO—(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.
    Type: Application
    Filed: November 12, 2018
    Publication date: November 19, 2020
    Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS), Ecole Nationale Superieure de Chimie, Institut de Recherche Pour le Developpement (IRD), Universite D'Aix-Marseille, Communaute Universites et Etablissements Universite Cote D Azur
    Inventors: Céline Crauste, Joseph Vercauteren, Fransisco Veas, Thierry Durand, Nicolas Blondeau
  • Proton-conductive electrochemical device with integrated reforming and associated production method
    Patent number: 10833344
    Abstract: A proton-conductive electrochemical device and method for manufacturing the device. The device comprising a positive electrode able to reduce an oxidizing species, a negative electrode able to oxidize a reducing species, and a proton-conductive electrolyte, in contact with the positive and negative electrode. The device further comprises a layer able to diffuse protons and electrons, and forms a protective barrier against contaminants for the electrolyte. The layer is in contact with both the electrolyte and the negative electrode, and comprises a material of the type ABB?O3 or a material of the type ABO3, wherein A is an element chosen from group II of the periodic table, B is an element chosen from cerium and group IVB of the periodic table, B? is an element chosen from lanthanides or group VIIIB of the periodic table, and the layer has a porosity of less than 10% by volume.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 10, 2020
    Assignees: ELECTRICITE DE FRANCE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS-
    Inventors: Mathieu Marrony, Gilles Taillades, Jacques Roziere, Julian Dailly
  • Quinoline derivatives for use in the treatment or prevention of viral infection
    Patent number: 10806729
    Abstract: The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: October 20, 2020
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
  • Quantum cascade laser
    Patent number: 10811846
    Abstract: The invention relates to a quantum cascade laser (300) comprising a gain region (102) inserted between two optical confinement layers (1041, 1042), said gain region (102) having an electron input into the gain region (102) and an electron output from said gain region (102) characterized in that said laser comprises a hole-blocking area (304) on the side of said electron output.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 20, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Roland Tessier, Alexei Baranov
  • Method for stimulating the resistance of plants to biotic stress by UV radiation exposure
    Patent number: 10806096
    Abstract: The present invention relates to a method for stimulating the resistance of plants to biotic stress by radiation exposure of at least one spot of a plant characterized in that the radiation exposure is performed by UV-C rays alone or UV-B rays alone or a combination thereof with an exposure duration being less or equal to one second and the radiation exposure being repeated at least once with an interval of time between one hour and one month. The invention will find an application for stimulating natural defenses of plants to biotic stress as pests, bacteria, fungus or virus. The invention could be used directly on plants growing in fields for agriculture and the food industry.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: October 20, 2020
    Assignees: UNIVERSITE D'AVIGNON ET DES PAYS DU VAUCLUSE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIF
    Inventors: Laurent Urban, Jawad Aarrouf, Dounyazade Chabane Sari, Bernard Orsal
  • MEAT ANALOGUES AND MEAT ANALOGUE EXTRUSION DEVICES AND METHODS
    Publication number: 20200323238
    Abstract: A meat analogue may include a macrostructure of connected sheared fibers oriented parallel to one another and gaps positioned between the sheared fibers. The macrostructure may include meat and may include a vegetable protein. An extrusion system may include an extruder and a die. The extrusion system may produce a meat analogue. A meat analogue may include an animal protein. The extruder may be connectable to the die. The extrusion system may be configured to direct a material including an animal protein from the extruder to the die and through a fluid path extending through the die. The die may be configured to inject a fat or a fat analogue into the material such that the fat or the fat analogue is embedded but visually distinct from the material including the animal protein when the fat or the fat analogue and the material exit the die.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 15, 2020
    Applicants: Université de Montpellier, Institut National de la Recherche Agronomique
    Inventors: Patrick Pibarot, Christophe Joseph Etienne Schmitt, Christian Sanchez, Marie-Héléne Morel
  • TEXTURIZED FOOD PRODUCTS CONTAINING INSOLUBLE PARTICLES AND METHODS FOR MAKING SUCH FOOD PRODUCTS
    Publication number: 20200323237
    Abstract: A meat analogue may include a set protein emulsion, the protein emulsion having a protein and at least one insoluble particle. In some embodiments, at least a portion of the particle can include at least one mineral material selected from the group consisting of silicium, and calcium, such as one or more of rhombohedral calcite, scalenohedral calcite, silicon dioxide, and magnesium oxide; at least one organic material selected from the group consisting of a bone meal, a cartilage meal, a ground crustacean shell, a ground sea fish shell, and a ground egg shell; and/or a gelled vegetable gum, a gelled hydrocolloid, a polymerized vegetable gum, a polymerized hydrocolloid, or a mixture thereof. The meat analogue can be made by extruding the protein emulsion and cooling the extruded emulsion. The meat analogue can be cut into chunks and/or added to another comestible composition such as a gravy or broth.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 15, 2020
    Applicants: Université de Montpellier, Institut National de la Recherche Agronomique
    Inventors: Patrick Pibarot, Christian Sanchez, Marie-Héléne Morel
  • Kinase and/or phosphatase sensing via hydroxyquinoline-sensitized chelates
    Patent number: 10799603
    Abstract: The present invention generally relates to assays of enzymes responsible for phosphoregulation including kinases (such as protein kinases, which mediate protein and peptide phosphorylation) and phosphatases (such as protein phosphatases, which mediate protein and peptide dephosphorylation). Certain aspects of the invention use lanthanide ions such as europium ions that exhibit chelation-enhanced luminescence. Phosphorylation of a peptide by a kinase may cause a complex to form between the lanthanide ion, the phosphate group, and a reporter group such as a hydroxyquinoline, which results in luminescence when in the complexed state. Thus, in certain embodiments, determination of luminescence may be indicative of kinase activity. Certain embodiments also include the use of substrates for detection of phosphatase activity, where dephosphorylation results in a loss of signal assay.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 13, 2020
    Assignees: Massachusetts Institute of Technology, Centre National de la Recherche Scientifique, ENSCM, UNIVERSITE DE MONTPELLIER
    Inventors: Barbara Imperiali, Juan Antonio González Vera
  • Organosilicon material for the decontamination of water
    Patent number: 10799850
    Abstract: The subject of the present invention is the use of a porous or non-porous organosilicon material for eliminating radionuclides, mineral anions, anionic molecular entities and negatively charged dyes or active principles from an aqueous solution, characterized in that the structure of said organosilicon material is formed of repeat units, each repeat unit comprising at least one positively charged entity selected from an ammonium entity, an imidazolium entity, a guanidinium entity, a pyridinium entity and a phosphonium entity and being incorporated into a silicon network by at least two silicon-carbon bonds. The invention also relates to a specific novel organosilicon material, comprising at least one benzyl group, one 4-phenylbenzyl group or one styrene group in each repeat unit.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: October 13, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, AXLR, SATT DU LANGUEDOC ROUSSILON (SATT AXLR)
    Inventors: Bénédicte Prelot, Peter Hesemann, Ut Dong Thach, Jerzy Zajac